Aksigen IVF has announced the publication of its second peer-reviewed international research paper, which calls for personalized, phenotype-driven and multi-modal IVF care for women with Polyendocrine Metabolic Ovarian Syndrome (PMOS), the new global terminology for polycystic ovary syndrome (PCOS). Published in Insights in Reproductive Medicine, the review draws on a decade of global evidence and highlights the need to tailor fertility treatment to a patient’s ovarian reserve, metabolic health, body weight, age and disease phenotype.
PMOS is among the most common endocrine disorders, affecting an estimated 6 to 13 percent of women globally and nearly one in four women in India. With almost 70 percent of cases believed to remain undiagnosed, the condition continues to be a major contributor to infertility while also raising risks linked to pregnancy and long-term metabolic health. The study says that addressing PMOS through individualized fertility care is essential not only for improving conception outcomes but also for protecting women’s broader health.
The review found that personalised IVF protocols can improve success rates, while safer stimulation strategies can significantly reduce treatment risks. It noted that GnRH antagonist protocols lower the risk of ovarian hyperstimulation syndrome by 42 percent without affecting pregnancy and live birth rates. It also highlighted GnRH agonist triggers and freeze-all embryo transfer strategies as important tools for lowering complications, while emerging approaches such as Progestin-Primed Ovarian Stimulation and In Vitro Maturation may offer additional options for high-risk patients.
Dr. Unnati Mamtora, Chief Fertility Consultant at Aksigen IVF, said the global renaming of PCOS to PMOS reflects the clinical reality that the condition is a multi-system disorder, not limited to the ovaries. She said Aksigen’s ROOTS Clinical Pathways are designed around this principle, with treatment decisions based on each patient’s ovarian reserve, metabolic profile, body weight, age and phenotype rather than a one-size-fits-all approach.
Dr. Shruti Salampuria-Sawant, Associate Fertility Specialist at Aksigen IVF, said balancing efficacy and safety is especially important in women with PMOS because of their higher risk of ovarian hyperstimulation syndrome. She said the review supports GnRH antagonist protocols as the preferred first-line option and notes that complementary approaches, such as GnRH agonist triggers and freeze-all transfers, can further improve safety without compromising outcomes.
The publication builds on Aksigen IVF’s earlier research on obesity and fertility outcomes and adds to the centre’s growing academic work in reproductive medicine. The team is also preparing a follow-up manuscript on a multi-system pre-IVF optimization framework based on the PMOS terminology, continuing its focus on evidence-based and patient-centred fertility care.
